Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Calculi | 11 | 2026 | 357 | 3.150 |
Why?
|
| Nephrolithiasis | 2 | 2024 | 24 | 1.640 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2022 | 268 | 1.240 |
Why?
|
| Nephrology | 3 | 2026 | 57 | 1.110 |
Why?
|
| Hypophosphatemia | 1 | 2026 | 10 | 0.950 |
Why?
|
| Diet, Vegetarian | 2 | 2022 | 8 | 0.930 |
Why?
|
| Phosphates | 1 | 2026 | 165 | 0.890 |
Why?
|
| Cystinuria | 2 | 2021 | 13 | 0.870 |
Why?
|
| Renal Agents | 1 | 2017 | 1 | 0.530 |
Why?
|
| Health Status Disparities | 1 | 2020 | 243 | 0.510 |
Why?
|
| Risk Reduction Behavior | 1 | 2017 | 102 | 0.500 |
Why?
|
| Ergocalciferols | 2 | 2007 | 38 | 0.480 |
Why?
|
| Hypertension | 1 | 2021 | 788 | 0.450 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 822 | 0.420 |
Why?
|
| Kidney Failure, Chronic | 2 | 2010 | 448 | 0.410 |
Why?
|
| Vitamin D Deficiency | 2 | 2022 | 118 | 0.390 |
Why?
|
| Fibroblast Growth Factors | 1 | 2010 | 89 | 0.300 |
Why?
|
| Risk Factors | 6 | 2026 | 6269 | 0.300 |
Why?
|
| Humans | 26 | 2026 | 98223 | 0.300 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2026 | 602 | 0.300 |
Why?
|
| Vitamins | 2 | 2022 | 92 | 0.280 |
Why?
|
| Kidney Transplantation | 2 | 2025 | 942 | 0.280 |
Why?
|
| Parathyroid Hormone | 2 | 2022 | 233 | 0.270 |
Why?
|
| Alcohol Drinking | 2 | 2009 | 301 | 0.250 |
Why?
|
| Calcium | 5 | 2025 | 1201 | 0.240 |
Why?
|
| Bone Diseases | 1 | 2006 | 51 | 0.230 |
Why?
|
| Smoking | 2 | 2009 | 676 | 0.230 |
Why?
|
| Bone Density Conservation Agents | 1 | 2005 | 53 | 0.220 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2005 | 73 | 0.220 |
Why?
|
| Dietary Supplements | 1 | 2026 | 152 | 0.220 |
Why?
|
| Lithotripsy | 1 | 2024 | 42 | 0.210 |
Why?
|
| Donor Selection | 1 | 2025 | 86 | 0.210 |
Why?
|
| Fellowships and Scholarships | 1 | 2026 | 164 | 0.210 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2024 | 38 | 0.200 |
Why?
|
| Aged | 10 | 2026 | 21824 | 0.200 |
Why?
|
| Diet | 3 | 2022 | 469 | 0.200 |
Why?
|
| Homeostasis | 1 | 2026 | 474 | 0.200 |
Why?
|
| Middle Aged | 12 | 2026 | 29494 | 0.190 |
Why?
|
| Referral and Consultation | 1 | 2026 | 418 | 0.190 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2023 | 89 | 0.190 |
Why?
|
| Biomarkers | 3 | 2020 | 2020 | 0.180 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2023 | 99 | 0.180 |
Why?
|
| Drinking | 1 | 2022 | 34 | 0.180 |
Why?
|
| Wakefulness | 1 | 2012 | 127 | 0.180 |
Why?
|
| Living Donors | 1 | 2025 | 375 | 0.180 |
Why?
|
| Education, Medical, Graduate | 1 | 2026 | 450 | 0.170 |
Why?
|
| Acute Kidney Injury | 1 | 2026 | 360 | 0.170 |
Why?
|
| Perception | 1 | 2022 | 187 | 0.170 |
Why?
|
| Curriculum | 1 | 2026 | 634 | 0.170 |
Why?
|
| Hypnotics and Sedatives | 1 | 2012 | 140 | 0.170 |
Why?
|
| Male | 13 | 2026 | 47195 | 0.160 |
Why?
|
| Renal Elimination | 1 | 2020 | 11 | 0.160 |
Why?
|
| Water-Electrolyte Balance | 1 | 2020 | 70 | 0.160 |
Why?
|
| Kidney | 2 | 2022 | 1121 | 0.160 |
Why?
|
| Female | 13 | 2026 | 51685 | 0.160 |
Why?
|
| Circadian Rhythm | 1 | 2012 | 295 | 0.150 |
Why?
|
| Urodynamics | 1 | 2020 | 130 | 0.150 |
Why?
|
| Respiration, Artificial | 1 | 2012 | 430 | 0.140 |
Why?
|
| Sleep | 1 | 2012 | 465 | 0.140 |
Why?
|
| Treatment Outcome | 3 | 2020 | 9750 | 0.130 |
Why?
|
| Adult | 9 | 2026 | 29548 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 1107 | 0.130 |
Why?
|
| Risk Assessment | 2 | 2026 | 2598 | 0.130 |
Why?
|
| Disease Progression | 1 | 2021 | 1612 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2026 | 2569 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2026 | 1123 | 0.120 |
Why?
|
| Chicago | 1 | 2020 | 1519 | 0.110 |
Why?
|
| Vitamin D | 2 | 2022 | 286 | 0.100 |
Why?
|
| Recurrence | 1 | 2017 | 1261 | 0.100 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2013 | 8 | 0.100 |
Why?
|
| Prevalence | 1 | 2017 | 1391 | 0.100 |
Why?
|
| Quality of Life | 1 | 2021 | 1897 | 0.090 |
Why?
|
| Calcium Channel Blockers | 1 | 2013 | 118 | 0.090 |
Why?
|
| Diuretics | 1 | 2013 | 78 | 0.090 |
Why?
|
| Incidence | 1 | 2017 | 1786 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 1946 | 0.090 |
Why?
|
| Surveys and Questionnaires | 3 | 2026 | 3030 | 0.090 |
Why?
|
| Oxalates | 1 | 2010 | 49 | 0.080 |
Why?
|
| Retrospective Studies | 3 | 2020 | 11031 | 0.080 |
Why?
|
| Minerals | 1 | 2010 | 21 | 0.080 |
Why?
|
| Hypercalciuria | 1 | 2010 | 47 | 0.080 |
Why?
|
| Animals | 2 | 2026 | 28950 | 0.080 |
Why?
|
| Kidney Tubules | 1 | 2010 | 91 | 0.080 |
Why?
|
| Age of Onset | 2 | 2009 | 368 | 0.070 |
Why?
|
| Bone and Bones | 1 | 2010 | 272 | 0.070 |
Why?
|
| Vaccinium macrocarpon | 1 | 2026 | 3 | 0.060 |
Why?
|
| Curcuma | 1 | 2026 | 5 | 0.060 |
Why?
|
| Acetic Acid | 1 | 2026 | 10 | 0.060 |
Why?
|
| Calcitriol | 1 | 2007 | 173 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2006 | 1009 | 0.060 |
Why?
|
| Sex Distribution | 1 | 2006 | 177 | 0.060 |
Why?
|
| Age Distribution | 1 | 2006 | 212 | 0.060 |
Why?
|
| Creatinine | 1 | 2026 | 313 | 0.060 |
Why?
|
| Calcium Phosphates | 1 | 2025 | 85 | 0.050 |
Why?
|
| United States | 3 | 2026 | 8252 | 0.050 |
Why?
|
| Plant Extracts | 1 | 2026 | 252 | 0.050 |
Why?
|
| Bone Density | 1 | 2006 | 248 | 0.050 |
Why?
|
| Calcium Oxalate | 1 | 2025 | 192 | 0.050 |
Why?
|
| Sensation | 1 | 2023 | 48 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2009 | 770 | 0.050 |
Why?
|
| Sleep, REM | 1 | 2012 | 49 | 0.050 |
Why?
|
| Lighting | 1 | 2012 | 31 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2012 | 64 | 0.050 |
Why?
|
| Melatonin | 1 | 2012 | 47 | 0.050 |
Why?
|
| Logistic Models | 1 | 2006 | 1275 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 1213 | 0.040 |
Why?
|
| Polysomnography | 1 | 2012 | 154 | 0.040 |
Why?
|
| Chest Tubes | 1 | 2001 | 21 | 0.040 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2001 | 29 | 0.040 |
Why?
|
| Smartphone | 1 | 2022 | 53 | 0.040 |
Why?
|
| Urinary Bladder | 1 | 2023 | 262 | 0.040 |
Why?
|
| Urinary Calculi | 1 | 2001 | 45 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 2012 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 1017 | 0.040 |
Why?
|
| Drainage | 1 | 2001 | 176 | 0.040 |
Why?
|
| Mass Screening | 1 | 2006 | 750 | 0.040 |
Why?
|
| Cystine | 1 | 2020 | 19 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2026 | 866 | 0.040 |
Why?
|
| Registries | 1 | 2006 | 1127 | 0.040 |
Why?
|
| Hospitalization | 1 | 2026 | 986 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2012 | 528 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2006 | 1186 | 0.040 |
Why?
|
| Critical Illness | 1 | 2012 | 361 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 4041 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 308 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2012 | 474 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2007 | 4815 | 0.030 |
Why?
|
| Time Factors | 2 | 2012 | 5573 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2007 | 7409 | 0.030 |
Why?
|
| Young Adult | 1 | 2026 | 7556 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2013 | 185 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1126 | 0.020 |
Why?
|
| Sex Factors | 1 | 2009 | 1142 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 1114 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2009 | 310 | 0.010 |
Why?
|
| Age Factors | 1 | 2009 | 1972 | 0.010 |
Why?
|
| Reoperation | 1 | 2001 | 730 | 0.010 |
Why?
|
| Aging | 1 | 2001 | 770 | 0.010 |
Why?
|